Market Cap 9.23M
Revenue (ttm) 0.00
Net Income (ttm) -5.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 39,390
Avg Vol 137,514
Day's Range N/A - N/A
Shares Out 21.41M
Stochastic %K 19%
Beta 1.37
Analysts Strong Sell
Price Target $8.00

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-smal...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 948 2356
Address:
2355 Westwood Blvd., Suite 139, Los Angeles, United States
Tracey11
Tracey11 Jun. 23 at 4:33 PM
$KAPA On Watch
0 · Reply
Oldshoe
Oldshoe Jun. 19 at 12:59 PM
$KAPA Holdings reports (13F-HR filings) for the most recently ended quarter (Q1) show Vanguard is the largest institutional holder of KAPA at 1.08% ownership. 13F-HR effective 3-31-2026, filed 5-15-2026. Large institutional investors are required to file form 13F-HR within 45 days of quarter end (hence the 3-31 effective date, 5-15 filing date). All of the shares (231,878) were purchased in Q1. Next required 13F-HR filings will be due by 45 days after 6/30 (end of Q2). To me this shows fairly good recent smart money buy interest - but should mention Vanguard Capital Management LLC appears to have around 4,000 holdings, KAPA being only one of those.
0 · Reply
Xtracked
Xtracked Jun. 18 at 2:26 PM
$KAPA Putting frustrations aside, I'll be voting YES for RS .If any collaboration deal is waiting, say J&J, they would require SP to be well over $1 to invest equity into company. I'm going to see this through...they need this to complete good deal IMHO. Trying to keep my head up ... getting destroyed. I lost a friend to cancer last year and broke the golden rule w this. I got emotionally attached. NOT FINANCIAL ADVICE
1 · Reply
ezcheezie
ezcheezie Jun. 17 at 1:07 PM
$KAPA 17 shares of volume at 9am is CRAZY!! Even for this stock. It's like Everyone is holding their breath for this symposium.
1 · Reply
Xtracked
Xtracked Jun. 15 at 12:28 PM
$KAPA So 2 weeks later, they changed their timelines. How convenient for them.
0 · Reply
Xtracked
Xtracked Jun. 15 at 12:21 PM
$KAPA May 19th LD Micro claims. June 4th, Jon Yu writes a letter..."Sorry I led you on w false timelines" And we are expected to believe this BS
0 · Reply
Oldshoe
Oldshoe Jun. 14 at 7:47 PM
$KAPA Previous phase 1 prostate cancer (PC) trials reported good safety/efficacy in separate studies (Tracon, Kairos). Expecting that to continue for PC phase 2 trial (late Q3 update expected). The NSCLC phase 1 trial is still in early steps, but expect update early/mid Q3. This is a risk trade/investment. Early-stage bio stocks are inherently unpredictable. Make your own decisions about any investments you make.
0 · Reply
Stocktwits182182
Stocktwits182182 Jun. 12 at 8:36 PM
$KAPA never again into biotechnology
0 · Reply
IMANEEDSMONEY
IMANEEDSMONEY Jun. 12 at 6:20 PM
$KAPA I Voted no
0 · Reply
uptrend2025
uptrend2025 Jun. 12 at 4:57 PM
$KAPA Interesting buys 👀
0 · Reply
Latest News on KAPA
Kairos Pharma Proxy statement: Proxy filing

May 26, 2026, 8:00 AM EDT - 4 weeks ago

Kairos Pharma Proxy statement: Proxy filing


Kairos Pharma Proxy statement: Proxy filing

May 22, 2026, 8:00 AM EDT - 4 weeks ago

Kairos Pharma Proxy statement: Proxy filing


Kairos Pharma Slides: Investor presentation

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Kairos Pharma Slides: Investor presentation


Kairos Pharma Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 5 weeks ago

Kairos Pharma Quarterly report: Q1 2026


Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

May 13, 2026, 5:30 AM EDT - 5 weeks ago

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI


Kairos Pharma Proxy statement: Proxy filing

May 11, 2026, 8:00 AM EDT - 6 weeks ago

Kairos Pharma Proxy statement: Proxy filing


Kairos Pharma Annual report: Q4 2025

Mar 31, 2026, 7:00 AM EDT - 3 months ago

Kairos Pharma Annual report: Q4 2025


Kairos Pharma to acquire CL-273 from Celyn Therapeutics

2026-03-02T11:53:03.000Z - 4 months ago

Kairos Pharma to acquire CL-273 from Celyn Therapeutics


Kairos Pharma Registration statement: Registration Filing

Jan 13, 2026, 7:00 AM EST - 5 months ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma files $75M mixed securities shelf

2026-01-13T11:05:46.000Z - 5 months ago

Kairos Pharma files $75M mixed securities shelf


Kairos Pharma Quarterly report: Q3 2025

Nov 14, 2025, 7:00 AM EST - 7 months ago

Kairos Pharma Quarterly report: Q3 2025


Kairos Pharma Provides Shareholder Update

Nov 4, 2025, 8:00 AM EST - 8 months ago

Kairos Pharma Provides Shareholder Update


Kairos Pharma Transcript: Study Update

Sep 18, 2025, 5:00 PM EDT - 9 months ago

Kairos Pharma Transcript: Study Update


Kairos Pharma Press release: Study Update

Sep 18, 2025, 5:00 PM EDT - 9 months ago

Kairos Pharma Press release: Study Update


Kairos Pharma announces interim efficacy analysis of ENV105

2025-09-18T12:16:01.000Z - 9 months ago

Kairos Pharma announces interim efficacy analysis of ENV105


Kairos Pharma Quarterly report: Q2 2025

Aug 12, 2025, 4:00 PM EDT - 11 months ago

Kairos Pharma Quarterly report: Q2 2025


Kairos Pharma management to meet with Maxim

2025-08-04T14:05:21.000Z - 11 months ago

Kairos Pharma management to meet with Maxim


Why Is Kairos Pharma Stock (KAPA) Up 170% Today?

2025-07-16T01:26:00.000Z - 1 year ago

Why Is Kairos Pharma Stock (KAPA) Up 170% Today?


Kairos Pharma Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing


Kairos Pharma, Ltd. Announces Participation in the D.

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma, Ltd. Announces Participation in the D.


Kairos Pharma Proxy statement: Proxy Filing

May 6, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing


Kairos Pharma Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Proxy statement: Proxy Filing


Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Ltd. Provides Letter to Stockholders


Kairos Pharma Registration statement: Registration Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Annual report: Q4 2024

Apr 14, 2025, 6:00 PM EDT - 1 year ago

Kairos Pharma Annual report: Q4 2024


Kairos Pharma initiated with a Buy at H.C. Wainwright

2025-04-03T10:16:23.000Z - 1 year ago

Kairos Pharma initiated with a Buy at H.C. Wainwright


Kairos Pharma completes safety lead-in of ENV105 trial

2025-03-31T11:11:12.000Z - 1 year ago

Kairos Pharma completes safety lead-in of ENV105 trial


Kairos Pharma initiated with a Buy at Maxim

2025-03-27T11:40:11.000Z - 1 year ago

Kairos Pharma initiated with a Buy at Maxim


Kairos Pharma announces new DoD funding for ENV205 research

2025-02-18T13:42:31.000Z - 1 year ago

Kairos Pharma announces new DoD funding for ENV205 research


Kairos Pharma Registration statement: Registration Filing

Jan 29, 2025, 7:00 AM EST - 1 year ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Provides Business Update and Outlook into 2025

Jan 21, 2025, 8:30 AM EST - 1 year ago

Kairos Pharma Provides Business Update and Outlook into 2025


IBN Initiates Coverage of Kairos Pharma Ltd.

Nov 26, 2024, 8:30 AM EST - 1 year ago

IBN Initiates Coverage of Kairos Pharma Ltd.


Kairos Pharma Quarterly report: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

Kairos Pharma Quarterly report: Q3 2024


Kairos Pharma Earnings release: Q3 2024

Nov 13, 2024, 6:00 PM EST - 1 year ago

Kairos Pharma Earnings release: Q3 2024


Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII


Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering


Kairos Pharma Prices $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering


Kairos Pharma Registration statement: Registration Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 24, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 20, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 13, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma Registration statement: Registration Filing

May 1, 2024, 8:00 AM EDT - 2 years ago

Kairos Pharma Registration statement: Registration Filing


Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Feb 14, 2024, 6:16 PM EST - 2 years ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each


Tracey11
Tracey11 Jun. 23 at 4:33 PM
$KAPA On Watch
0 · Reply
Oldshoe
Oldshoe Jun. 19 at 12:59 PM
$KAPA Holdings reports (13F-HR filings) for the most recently ended quarter (Q1) show Vanguard is the largest institutional holder of KAPA at 1.08% ownership. 13F-HR effective 3-31-2026, filed 5-15-2026. Large institutional investors are required to file form 13F-HR within 45 days of quarter end (hence the 3-31 effective date, 5-15 filing date). All of the shares (231,878) were purchased in Q1. Next required 13F-HR filings will be due by 45 days after 6/30 (end of Q2). To me this shows fairly good recent smart money buy interest - but should mention Vanguard Capital Management LLC appears to have around 4,000 holdings, KAPA being only one of those.
0 · Reply
Xtracked
Xtracked Jun. 18 at 2:26 PM
$KAPA Putting frustrations aside, I'll be voting YES for RS .If any collaboration deal is waiting, say J&J, they would require SP to be well over $1 to invest equity into company. I'm going to see this through...they need this to complete good deal IMHO. Trying to keep my head up ... getting destroyed. I lost a friend to cancer last year and broke the golden rule w this. I got emotionally attached. NOT FINANCIAL ADVICE
1 · Reply
ezcheezie
ezcheezie Jun. 17 at 1:07 PM
$KAPA 17 shares of volume at 9am is CRAZY!! Even for this stock. It's like Everyone is holding their breath for this symposium.
1 · Reply
Xtracked
Xtracked Jun. 15 at 12:28 PM
$KAPA So 2 weeks later, they changed their timelines. How convenient for them.
0 · Reply
Xtracked
Xtracked Jun. 15 at 12:21 PM
$KAPA May 19th LD Micro claims. June 4th, Jon Yu writes a letter..."Sorry I led you on w false timelines" And we are expected to believe this BS
0 · Reply
Oldshoe
Oldshoe Jun. 14 at 7:47 PM
$KAPA Previous phase 1 prostate cancer (PC) trials reported good safety/efficacy in separate studies (Tracon, Kairos). Expecting that to continue for PC phase 2 trial (late Q3 update expected). The NSCLC phase 1 trial is still in early steps, but expect update early/mid Q3. This is a risk trade/investment. Early-stage bio stocks are inherently unpredictable. Make your own decisions about any investments you make.
0 · Reply
Stocktwits182182
Stocktwits182182 Jun. 12 at 8:36 PM
$KAPA never again into biotechnology
0 · Reply
IMANEEDSMONEY
IMANEEDSMONEY Jun. 12 at 6:20 PM
$KAPA I Voted no
0 · Reply
uptrend2025
uptrend2025 Jun. 12 at 4:57 PM
$KAPA Interesting buys 👀
0 · Reply
joaneegell
joaneegell Jun. 10 at 5:00 PM
$KAPA finally closed out at a loss. fuck this company and fuck the pumpers. glta
2 · Reply
Oldshoe
Oldshoe Jun. 9 at 2:10 PM
$KAPA Kapa's a Delaware corporation. Voting should follow Delaware voting standards for shareholder meetings (DGCL standards). To actually cast a vote and have it recorded you would either need to vote FOR or AGAINST. Not voting doesn't count as a vote either way - no vote would be recorded in that case. You can vote on some, none, or all of the items that will be voted on - there are several different items that are up for vote. That's about it.
1 · Reply
Xtracked
Xtracked Jun. 9 at 1:29 PM
$KAPA Has had plenty of time to choreograph this show. I paid too much for my seat, and Jon has strung us out too far. Time to repay the shareholders supporting the hope. I'm sure of which many have lost someone to cancer. Just a little more PAIN from us is what they want. Fk sake
0 · Reply
Xtracked
Xtracked Jun. 9 at 1:15 PM
$KAPA I may be wrong on this, seems to be different regulations on this. Either way, w insider ownership and low retail vote turnout, this will most likely be approved across the board.
0 · Reply
TraderBuckNKY
TraderBuckNKY Jun. 8 at 10:07 PM
$KAPA good volume earlier today...is there a change in the wind...https://www.youtube.com/watch?v=t1sYjDc8i4I
0 · Reply
Xtracked
Xtracked Jun. 8 at 1:34 PM
$KAPA RETAIL ...If you do NOT vote , it will count as a YES . I suspect it wlll all pass.
0 · Reply
Oldshoe
Oldshoe Jun. 5 at 10:46 PM
$KAPA Fyi. Three daily support levels - 0.44, 0.43, ATL @ 0.40. To me an intra-day break above 0.5000 likely would indicate renewed market interest (0.4999 double top today, yesterday). Believe 0.44 likely holds remainder of today, also believe pre-6/29 bottom is here or within next week (6/29 is shareholder meeting, would expect possible change could occur then up or down). Sitting underwater along with no doubt most others, not happy with that but holding steady and longer term bullish. Opinion only, not financial advice. ALWAYS use your own judgement on any trades or investments.
1 · Reply
SuperGreenToday
SuperGreenToday Jun. 5 at 5:30 PM
0 · Reply
uptrend2025
uptrend2025 Jun. 5 at 1:44 PM
0 · Reply
Ahdayesh
Ahdayesh Jun. 5 at 1:14 PM
$KAPA 🚀🚀🚀
0 · Reply
Oldshoe
Oldshoe Jun. 5 at 1:37 AM
$KAPA I'm voting to authorize the board to do a reverse split if they determine it's necessary. Not giving them the authority to do that means KAPA could become an over the counter (OTC) stock - essentially untradeable. If the company were listed with NYSE or Nasdaq they'd be required to meet minimum bid requirement by 7/03-7/06 (by my calculations), but they're listed with NYSE American (Amex) so there should be more leeway about the date (NYSE American uses more judgement-based discretionary guidelines about minimum bid). But I expect that would still put the apparent need for it in July/August - roughly same time frame as upcoming catalysts which could significantly increase stock price. Expecting a run-up to catalysts after - or possibly before - s/h approval of possible r/s. My opinion only - not financial advice.
1 · Reply
ChrisBAB
ChrisBAB Jun. 4 at 10:05 PM
0 · Reply